Blood Biomarkers: Democratizing Alzheimer’s Diagnostics.
NEURON | JUNE 17, 2020
Zetterberg H and Blennow K
Currently available biomarkers for Alzheimer’s disease are of limited availability due to high costs and perceived invasiveness. New studies reveal that Alzheimer’s pathologies now can be reliably quantified in vivo using regular blood tests.
Share this page